BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

Outlook (OTLK)OutlookFDA / regulatory

Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™ Access the segment here ISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Related news

OTLKOutlook2026-06-16 12:02 EST

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

OTLKOutlook2026-06-01 12:46 EST

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

LENZLenz Therapeutics Inc2026-06-07 23:30 EST

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

OCGNOcugen2026-09-25 11:02 EST

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

OCULOcular Therapeutix2026-06-17 12:45 EST

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

RHHBYRoche Holdings AG2026-07-24 10:15 EST

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

TARSTarsus Pharmaceuticals2026-07-08 20:05 EST

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

RHHBYRoche Holdings AG2026-09-18 10:45 EST

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

View all latest news

Outlook

Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...

Recent company news

OTLKOutlook2026-10-06 13:20 EST

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

OTLKOutlook2026-10-01 13:01 EST

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-09-11 11:00 EST

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

OTLKOutlook2026-09-10 13:10 EST

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

OTLKOutlook2026-08-27 20:05 EST

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Stock data

Close
0.57 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States